化疗相关性腹泻的发生机制和治疗策略

被引：60

作者：

方青芳

机构：

[1] 浙江省肿瘤医院药剂科

来源：

中国临床药理学与治疗学 | 2009年 / 14卷 / 03期

关键词：

化疗相关性腹泻; 伊立替康; 5-FU; 机制; 治疗策略;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

化疗相关性腹泻(chemotherapy-induced diarrhea,CID)是肿瘤患者化疗中常见的并发症,不仅会降低患者的体质和生活质量,严重者导致化疗被迫中断,从而影响疗效。许多化疗药物都可以引起腹泻,其中以氟尿嘧啶类(fluorouracil)和伊立替康(irinotecan,CPT-11)的腹泻发生率最高。本文通过对相关化疗药物(主要是5-FU和CPT-11)引起CID的发生机制和治疗策略进行综述,探讨临床有效防治CID的措施。

引用

页码：351 / 355

页数：5

共 11 条

[1]

Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy [J].

Grau, Juan J. ;

Caballero, Miguel ;

Monzo, Mariano ;

Munoz-Garcia, Carmen ;

Domingo-Domenech, Jose ;

Navarro, Alfons ;

Conill, Carlos ;

Campayo, Marc ;

Bombi, Jose A. .

JOURNAL OF SURGICAL ONCOLOGY, 2008, 98 (02) :130-134

[2]

UGT1A1*28 and Other UGT1A Polymorphisms as Determinants of Irinotecan Toxicity.[J].Biason;Masier;Toffoli.Journal of Chemotherapy.2008, 2

[3]

Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies [J].

Gibson, Rachel J. ;

Keefe, Dorothy M. K. .

SUPPORTIVE CARE IN CANCER, 2006, 14 (09) :890-900

[4]

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea [J].

Sharma, R ;

Tobin, P ;

Clarke, SJ .

LANCET ONCOLOGY, 2005, 6 (02) :93-102

[5]

Overview of chemotherapy-induced diarrhea.[J].Carol S Viele.Seminars in Oncology Nursing.2003,

[6]

Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer [J].

Masanori Terashima ;

Hisataka Fujiwara ;

Akinori Takagane ;

Kaoru Abe ;

Takashi Irinoda ;

Tsutomu Nakaya ;

Hitoshi Yonezawa ;

Kenichi Oyama ;

Kazuyoshi Saito ;

Norio Kanzaki ;

Satoshi Ohtani ;

Tsuyoshi Nemoto ;

Yutaka Hoshino ;

Michihiko Kogure ;

Mitsukazu Gotoh .

Gastric Cancer, 2003, 6 (Suppl 1) :71-81

[7]

Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer [J].

Shirota, Y ;

Ichikawa, W ;

Uetake, H ;

Yamada, H ;

Nihei, Z ;

Sugihara, K .

ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (06) :599-603

[8]

Management of Cancer Treatment–Related Diarrhea.[J].Steven Kornblau;Al B. Benson;Robert Catalano;Richard E. Champlin;Constance Engelking;Michael Field;Cindy Ippoliti;Hillard M. Lazarus;Edith Mitchell;Joseph Rubin;Patrick J. Stiff;Everett Vokes;Scott Wadler.Journal of Pain and Symptom Management.2000, 2

[9]

Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats [J].